Research ExplorerPublicationsQuality of life measurement in alopecia areata. Position sta...

Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes

Standard

Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. / Chernyshov, P V; Tomas-Aragones, L; Finlay, A Y; Manolache, L; Marron, S E; Sampogna, F; Spillekom-van Koulil, S; Pustisek, N; Suru, A; Evers, A W M; Salavastru, C; Svensson, A; Abeni, D; Blome, C; Poot, F; Jemec, G B E; Linder, D; Augustin, M; Bewley, A; Salek, S S; Szepietowski, J C.

In: J EUR ACAD DERMATOL, Vol. 35, No. 8, 08.2021, p. 1614-1621.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Chernyshov, PV, Tomas-Aragones, L, Finlay, AY, Manolache, L, Marron, SE, Sampogna, F, Spillekom-van Koulil, S, Pustisek, N, Suru, A, Evers, AWM, Salavastru, C, Svensson, A, Abeni, D, Blome, C, Poot, F, Jemec, GBE, Linder, D, Augustin, M, Bewley, A, Salek, SS & Szepietowski, JC 2021, 'Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes', J EUR ACAD DERMATOL, vol. 35, no. 8, pp. 1614-1621. https://doi.org/10.1111/jdv.17370

APA

Chernyshov, P. V., Tomas-Aragones, L., Finlay, A. Y., Manolache, L., Marron, S. E., Sampogna, F., Spillekom-van Koulil, S., Pustisek, N., Suru, A., Evers, A. W. M., Salavastru, C., Svensson, A., Abeni, D., Blome, C., Poot, F., Jemec, G. B. E., Linder, D., Augustin, M., Bewley, A., ... Szepietowski, J. C. (2021). Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J EUR ACAD DERMATOL, 35(8), 1614-1621. https://doi.org/10.1111/jdv.17370

Vancouver

Chernyshov PV, Tomas-Aragones L, Finlay AY, Manolache L, Marron SE, Sampogna F et al. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J EUR ACAD DERMATOL. 2021 Aug;35(8):1614-1621. https://doi.org/10.1111/jdv.17370

Bibtex

@article{7624e64007cd4d0b97842c15310c8e42,
title = "Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes",
abstract = "New treatment options may lead to an increased interest in using reliable and sensitive instruments to assess health-related quality of life in people with alopecia areata (AA). The purpose of this paper is to present current knowledge about quality of life assessment in AA. The dermatology-specific Dermatology Life Quality Index (DLQI) was the most widely reported health-related quality of life instrument used in AA. Three AA-specific (Alopecia Areata Symptom Impact Scale, Alopecia Areata Quality of Life Index and Alopecia Areata Patients' Quality of Life) and three hair disease-specific instruments (Hairdex, Scalpdex and 'hair-specific Skindex-29') were identified with a range of content and validation characteristics: there is little evidence yet of the actual use of these measures in AA. Scalpdex is the best-validated hair disease-specific instrument. Further extensive validation is needed for all of the AA-specific instruments. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommends the use of the dermatology-specific DLQI questionnaire, hair disease-specific Scalpdex and the alopecia areata-specific instruments the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index, despite the limited experience of their use. We hope that new treatment methods will be able to improve both clinical signs and health-related quality of life in patients with AA. In order to assess the outcomes of trials on these new treatment methods, it would be helpful when further development and validation of AA-specific instruments is being encouraged and also conducted.",
keywords = "Alopecia Areata, Dermatology, Hair, Humans, Quality of Life, Venereology",
author = "Chernyshov, {P V} and L Tomas-Aragones and Finlay, {A Y} and L Manolache and Marron, {S E} and F Sampogna and {Spillekom-van Koulil}, S and N Pustisek and A Suru and Evers, {A W M} and C Salavastru and A Svensson and D Abeni and C Blome and F Poot and Jemec, {G B E} and D Linder and M Augustin and A Bewley and Salek, {S S} and Szepietowski, {J C}",
note = "{\textcopyright} 2021 European Academy of Dermatology and Venereology.",
year = "2021",
month = aug,
doi = "10.1111/jdv.17370",
language = "English",
volume = "35",
pages = "1614--1621",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes

AU - Chernyshov, P V

AU - Tomas-Aragones, L

AU - Finlay, A Y

AU - Manolache, L

AU - Marron, S E

AU - Sampogna, F

AU - Spillekom-van Koulil, S

AU - Pustisek, N

AU - Suru, A

AU - Evers, A W M

AU - Salavastru, C

AU - Svensson, A

AU - Abeni, D

AU - Blome, C

AU - Poot, F

AU - Jemec, G B E

AU - Linder, D

AU - Augustin, M

AU - Bewley, A

AU - Salek, S S

AU - Szepietowski, J C

N1 - © 2021 European Academy of Dermatology and Venereology.

PY - 2021/8

Y1 - 2021/8

N2 - New treatment options may lead to an increased interest in using reliable and sensitive instruments to assess health-related quality of life in people with alopecia areata (AA). The purpose of this paper is to present current knowledge about quality of life assessment in AA. The dermatology-specific Dermatology Life Quality Index (DLQI) was the most widely reported health-related quality of life instrument used in AA. Three AA-specific (Alopecia Areata Symptom Impact Scale, Alopecia Areata Quality of Life Index and Alopecia Areata Patients' Quality of Life) and three hair disease-specific instruments (Hairdex, Scalpdex and 'hair-specific Skindex-29') were identified with a range of content and validation characteristics: there is little evidence yet of the actual use of these measures in AA. Scalpdex is the best-validated hair disease-specific instrument. Further extensive validation is needed for all of the AA-specific instruments. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommends the use of the dermatology-specific DLQI questionnaire, hair disease-specific Scalpdex and the alopecia areata-specific instruments the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index, despite the limited experience of their use. We hope that new treatment methods will be able to improve both clinical signs and health-related quality of life in patients with AA. In order to assess the outcomes of trials on these new treatment methods, it would be helpful when further development and validation of AA-specific instruments is being encouraged and also conducted.

AB - New treatment options may lead to an increased interest in using reliable and sensitive instruments to assess health-related quality of life in people with alopecia areata (AA). The purpose of this paper is to present current knowledge about quality of life assessment in AA. The dermatology-specific Dermatology Life Quality Index (DLQI) was the most widely reported health-related quality of life instrument used in AA. Three AA-specific (Alopecia Areata Symptom Impact Scale, Alopecia Areata Quality of Life Index and Alopecia Areata Patients' Quality of Life) and three hair disease-specific instruments (Hairdex, Scalpdex and 'hair-specific Skindex-29') were identified with a range of content and validation characteristics: there is little evidence yet of the actual use of these measures in AA. Scalpdex is the best-validated hair disease-specific instrument. Further extensive validation is needed for all of the AA-specific instruments. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes recommends the use of the dermatology-specific DLQI questionnaire, hair disease-specific Scalpdex and the alopecia areata-specific instruments the Alopecia Areata Symptom Impact Scale or Alopecia Areata Quality of Life Index, despite the limited experience of their use. We hope that new treatment methods will be able to improve both clinical signs and health-related quality of life in patients with AA. In order to assess the outcomes of trials on these new treatment methods, it would be helpful when further development and validation of AA-specific instruments is being encouraged and also conducted.

KW - Alopecia Areata

KW - Dermatology

KW - Hair

KW - Humans

KW - Quality of Life

KW - Venereology

U2 - 10.1111/jdv.17370

DO - 10.1111/jdv.17370

M3 - SCORING: Journal article

C2 - 34107093

VL - 35

SP - 1614

EP - 1621

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 8

ER -